Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose

Abstract

Following a single dose of efavirenz, an association between pharmacokinetics and neuropsychometric performance was discernable. A weaker association between genotype and neurocognitive test performance is likely mediated by effect of genotype on plasma clearance. Strategies that lower Cmax during initial dosing may decrease CNS side effects.